Use of methotrexate in patients with ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Haibel, H ^a   Sieper, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; Methotrexate; Spondylarthritis; Treatment

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MOBILIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SACROILIITIS; TREATMENT DURATION; ASESSEMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CRITERIA; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; DRUG RESPONSE; DRUG SAFETY; DRUG SURVIVAL; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PSORIATIC ARTHRITIS; SURVIVAL;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650574916     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. JOHNSEN K, GRAN JT, DALE K, HUSBY G: The prevalence of ankylosing spondylitis among Norwegian Samis (Lapps). J Rheumatol 1992;19:1591-4.
3. SPADARO A, RICCIERI V, SILI-SCAVALLIA et al.: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
4. BRAUN J, SIEPER J: Ankylosing spondylitis. Lancet 2007;369:1379-90.
5. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
6. RUDWALEIT M, KHAN MA, SIEPER J: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
7. RUDWALEIT M, BRAUN J, SIEPER J: (ASAS classification criteria for axial spondyloarthritis). Z Rheumatol 2009;68:591-3.
8. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
9. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (AS-SERT). Arthritis Rheum 2005;52:582-91.
10. VAN DER HEIJDE D, KIVITZ A, SCHIFF MH et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
11. DAVIS JC, JR., VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
12. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
13. INMAN RD, DAVIS JC Jr, HEIJDE D et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
14. DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
15. CHEN J, LIU C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005: CD004800.
16. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
17. HEIBERG MS, NORDVAG BY, MIKKELSEN K et al.: The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
18. WARD MM, KUZIS S: Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum 2002;47:234-41.
19. GLINTBORG B, OSTERGAARD M, KROGH NS et al.: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DAN-BIO registry. Ann Rheum Dis 2010, May 28 [Epub ahead of print].
20. HEIBERG MS, KOLDINGSNES W, MIKKELSEN K et al.: The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
21. ALTAN L, BINGOL U, KARAKOC Y et al.: Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
22. ROYCHOWDHURY B, BINDEY-BAGOT S, HUNT T, TUNN E: Methotrexate in severe ankylosing spondylitis - a randomized placebo-controlled study. Rheumatology 2001;40(Suppl. 1): S43.
23. GONZALEZ-LOPEZ L, GARCIA-GONZALEZ A, VAZQUEZ-DEL-MERCADO M et al.: Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004;31:1568-74.
24. SAMPAIO-BARROS PD, COSTALLAT LT, BERTOLO MB et al.: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
25. CHEN J, LIU C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004: CD004524.
26. HAIBEL H, BRANDT HC, SONG IH et al.: No efficacy of subcutaneous methotrexate in active ankylosing spondylitis - a 16 weeks open label trial. Ann Rheum Dis 2007;66:419-21.
27. KABASAKAL Y, KITAPCIOGLU G, YARGUCU F et al.: Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatol Int 2009;29:1523-7.
28. BREBAN M, RAVAUD P, CLAUDEPIERRE P et al.: No Superiority of Infliximab (INF) + Methotrexate (MTX) over INF Alone in the Treatment of Ankylosing Spondylitis (AS): Results of a One-Year Randomized Prospective Study. Arthritis Rheum 2005;52(9, Suppl.): S214.
29. LI EK, GRIFFITH JF, LEE VW et al.: Shortterm efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008;47:1358-63.
30. PEREZ-GUIJO VC, CRAVO AR, CASTRO M DEL C et al.: Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 2007;74:254-8.
31. MARZO-ORTEGA H, MCGONAGLE D, JARRETT S et al.: Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005;64:1568-75.